|
EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG
/ Key word(s): Annual Results/Forecast
Berlin, 30 March 2023 - Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) achieved sales of € 222.3 million in FY 2022. Compared to the previous year, sales increased by € 41.9 million or 23%. Net income reached € 29.3 million, thus increasing by nearly 20% compared to the previous year's figure adjusted for special effects. In the Isotope Products segment, sales rose by 37% to € 131.4 million. The reason for the increase is the acquisition of the Argentinian Tecnonuclear S.A. in 2022 and a strong Asian business. In the Medical segment, revenue grew by 8% to € 90.9 million. The largest growth driver continues to be the business with radiopharmaceuticals, which showed growth of 37% to Cash and cash equivalents as of 31 December 2022 decreased to € 82.7 million; less loan liabilities, net liquidity amounted to € 60.3 million. Compared to the end of 2021, this corresponds to a decrease of € 27.6 million. For the 2023 financial year, the Executive Board expects to achieve revenues of nearly € 230 million in the operating segments - Medical and Isotopes Products - and, as in 2022, a net profit of € 31 million. No revenues are expected in the Other segment. However, higher expenses for non-capitalizable clinical developments will occur in this segment in 2023, which will increase the loss in the Other segment by € 4 million to € 6 million. The consolidated net income (net profit) as the total of all segments will then amount to around € 25 million in 2023. The forecast is based on a weighted average exchange rate of USD 1.05 per euro and the assumption that Eckert & Ziegler will not be affected by any major disruptions from the war in Ukraine. The Executive Board and Supervisory Board will propose a dividend of € 0.50 per dividend-bearing share (previous year € 0.50) at the Annual General Meeting. The full 2022 financial statements can be found here: About Eckert & Ziegler.
30.03.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
| Language: | English |
| Company: | Eckert & Ziegler Strahlen- und Medizintechnik AG |
| Robert-Rössle-Str.10 | |
| 13125 Berlin | |
| Germany | |
| Phone: | +49 30 941084-138 |
| Fax: | +49 30 941084-112 |
| E-mail: | karolin.riehle@ezag.de |
| Internet: | www.ezag.de |
| ISIN: | DE0005659700 |
| WKN: | 565970 |
| Indices: | SDAX, TecDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1594623 |
| End of News | EQS News Service |
|
|
1594623 30.03.2023 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
